Color Health launches its first product to help make healthcare more affordable, accessible, and actionable.

In 2015, Color launched with a new clinical genetic testing model to help patients understand and take action on their personal risk of cancer. Our first product tested for BRCA1, BRCA2, and 17 other genes that increase an individual’s cancer risk. At the time, genetic tests for ovarian and breast cancer risk typically cost several thousand dollars, and access was often gated through long wait times for genetic counseling appointments at centers of excellence. Color was the first to deliver comprehensive genetic testing—including genetic counseling, at-home sample collection, and easy-to-understand reports—for less than a tenth of the cost. This affordable model has helped hundreds of thousands of individuals take action on their genetic risk.

Learn how Color worked with the Teamsters Health and Welfare Fund of Philadelphia and Vicinity to change how employees engaged with preventive care by better understanding their risk of cancer and other genetic diseases.

Color begins a long history of partnering with leaders in research and precision medicine, including the National Institutes of Health.

In 2018, the National Institutes of Health (NIH) awarded funding to Color, in partnership with the Broad Institute of MIT and Harvard, to establish one of three genome centers for its historic All of Us Research Program, a one million-participant program aimed at helping researchers better understand long-term health outcomes across the U.S. Color was initially selected to analyze and report genomic data for a set of 59 genes that cause conditions such as breast and ovarian cancer, hypercholesterolemia, Lynch syndrome, and more. Since then, Color has become the genetic counseling resource for all 1 million participants, the single home for test reporting, and the provider of ongoing participant engagement.

Since launching, the program has gathered data from hundreds of thousands of participants, over 80% of whom come from populations that have been historically underrepresented in clinical research. Our work with the NIH is the largest of our major research collaborations but not the last. We have since gone on to work with research institutions such as the Mayo Clinic, the Fred Hutchinson Cancer Research Center, and the University of Chicago and many local, state, and Federal governments.

Learn about an important NIH and Color partnership milestone—processing 100,000 genetic results for the All of Us Program—bealow.

Color partners with the American Cancer Society to operationalize a joint mission of ending cancer as we know it.

In June 2023, Color and the American Cancer Society (ACS) introduced a cancer screening and prevention program for employers and labor organizations, combining the ACS’s expertise in cancer screening, prevention, and risk reduction with Color’s leadership in population-scale healthcare delivery.

Rates of cancer screening, stage of detection, and treatment outcomes reflect some of the deepest disparities in American healthcare. With 159 million Americans receiving healthcare coverage through their employer, the ACS and Color recognize the critical role employers play in removing barriers of access to timely and quality preventive care. Hear from Hasbro employee and cancer patient, Gina, on the importance of early detection and employer support for cancer patients and caregivers below.

In the continuing spirit of access, the White House recently highlighted our joint pledge with the American Cancer Society to provide free at-home colorectal cancer screenings for uninsured and under-insured individuals. Read the White House Fact Sheet to learn more about the commitments made from other employers and industry leaders.

We are reinventing cancer care to deliver when it matters most.

In 2025, Color advanced its mission to deliver faster, more connected, and more expert-led cancer care for people across the entire cancer journey. Our oncologist-led Virtual Cancer Clinic continued to challenge the assumptions of a system that remains too slow and too fragmented for the realities of cancer today. By focusing on speed, access, and direct clinical care, we helped reduce uncertainty for patients, eased pressure on families, and gave organizations a more effective way to support their populations.

Throughout 2025, Color delivered care that met people wherever they were in their journey. We provided earlier answers through proactive outreach and comprehensive clinical assessment, accelerated time to diagnosis, and offered specialist guidance at the high-stakes moments when decisions matter most. Our care teams stayed closely connected to patient during active treatment, offering support and reassurance through some of the hardest moments of the experience, and intervening early to prevent complications, reduce emergency visits, and keep people on their treatment path. Survivors received structured screening plans and whole-person follow up to support long-term health, reduce recurrence risk, and create a more stable transition back to life and work.

The impact of this work was clear. In 2025, Color improved screening adherence, closed care gaps, accelerated time to active treatment, and delivered measurable savings for employers, unions, public-sector organizations, and health plans. Most importantly, people received care that felt more responsive, more personal, and more supportive than what the traditional system often provides. As we look ahead, our mission remains unchanged: to deliver a model of cancer care that brings clarity, expertise, and timely action to every person who needs it.